Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

Inclusion Criteria: 1. Provision of signed and dated informed consent form from a participant or legally authorized representative (LAR); 2. Male or female, \>18 years old; 3. Hospitalized participants with a laboratory diagnosis of COVID-19 infection 4. Evidence of persistent AKI as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (Table 3); 5. Willing to adhere to the study intervention regimen; Exclusion Criteria: 1. Hypersensitivity to nicotinamide riboside (NR); 2. Pregnant or lactating women confirmed with positive laboratory pregnancy tests as per local requirements; 3. eGFR \<15 mL/min/1.73 m2 as per the Chronic Kidney Disease Epidemiology Collaboration equation at admission lab; 4. Maintenance renal replacement therapy or initiation of renal replacement therapy before randomization 5. Currently on NR or nicotinamide or vitamin B3 (niacin) supplementation (multivitamins are allowed); 6. Concomitant cirrhosis of liver or acute liver failure; 7. Any medical history or condition that might, in the opinion of the attending physician, put the participant at significant risk if he/she were to participate in the trial; 8. Individuals with kidney transplant; 9. Individuals with blood platelet count \<100,000/microL